The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs

被引:6
|
作者
Pombo-Suarez, Manuel [2 ]
Gomez-Reino, Juan [1 ]
机构
[1] Hosp Clin Univ, Fdn Ramon Dominguez, Santiago De Compostela, Spain
[2] Hosp Clin Univ, Rheumatol Serv, Santiago De Compostela, Spain
关键词
Adverse event; Biologic agent; Biologic disease-modifying antirheumatic drug; Effectiveness; Observational study; Real-word evidence; Registry; Rheumatoid arthritis; Rheumatology; Safety; NECROSIS-FACTOR INHIBITORS; ANTI-TNF THERAPY; BRITISH SOCIETY; SERIOUS INFECTIONS; FACTOR ANTAGONISTS; CLINICAL-PRACTICE; ANKYLOSING-SPONDYLITIS; CARDIOVASCULAR EVENTS; PSORIATIC-ARTHRITIS; TUBERCULOSIS RISK;
D O I
10.1016/j.phrs.2019.104410
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Registries characterize the effectiveness and safety of therapeutic interventions in daily clinical practice. Data from registries enable mining the records of tens of thousands of patients towards determining the effectiveness, safety, and cost-benefit of any given therapeutic. The strengths of registries include real-life settings, greater power than clinical trials to detect rare events, and the study of multiple outcomes and several research questions. Registries also have their weaknesses. They are expensive, less accurate than clinical trials, affected by channelling bias, often require links to external sources or use historic and selected control cohorts or combine datasets to increase power, and have the risk of multiple confounders. Since the beginning of biological era, registries were developed to profile emerging treatments. This article reviews the role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    [J]. RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [2] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Xerxes Pundole
    Natalia V. Zamora
    Harish Siddhanamatha
    Heather Lin
    Jean Tayar
    Leung Cheuk Hong
    Liang Li
    Maria E. Suarez-Almazor
    [J]. Clinical Rheumatology, 2020, 39 : 787 - 794
  • [3] Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer
    Pundole, Xerxes
    Zamora, Natalia V.
    Siddhanamatha, Harish
    Lin, Heather
    Tayar, Jean
    Hong, Leung Cheuk
    Li, Liang
    Suarez-Almazor, Maria E.
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 787 - 794
  • [4] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    [J]. CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [5] Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
    Das, Priyam
    Weisenfeld, Dana
    Dahal, Kumar
    De, Debsurya
    Feathers, Vivi
    Coblyn, Jonathan S.
    Weinblatt, Michael E.
    Shadick, Nancy A.
    Cai, Tianxi
    Liao, Katherine P.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [6] Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
    Priyam Das
    Dana Weisenfeld
    Kumar Dahal
    Debsurya De
    Vivi Feathers
    Jonathan S. Coblyn
    Michael E. Weinblatt
    Nancy A. Shadick
    Tianxi Cai
    Katherine P. Liao
    [J]. Arthritis Research & Therapy, 25
  • [7] SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS ON THE TREATMENT WITH BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Hasegawa, E.
    Ito, S.
    Kurosawa, Y.
    Taniguchi, S.
    Kobayashi, D.
    Abe, A.
    Otani, H.
    Nakazono, K.
    Murasawa, A.
    Narita, I.
    Ishikawa, H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 985 - 985
  • [8] Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Saito, Shuntaro
    Kondo, Yasushi
    Kaneko, Yuko
    [J]. CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1373 - 1378
  • [9] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [10] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
    Haibel, H.
    Specker, C.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163